Cargando…

2018: The translational integrator: Facilitating collaboration and bridging the “Valley of Death”

OBJECTIVES/SPECIFIC AIMS: Translating conventional and regenerative medicine strategies from the research laboratory into the clinic is a complex process that can delay bringing novel therapies to the patient. Navigating the increasingly complex regulation surrounding cell-based and combination prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Joelle Greenberg, Alexandra, Staff, Nathan P., Windebank, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799662/
http://dx.doi.org/10.1017/cts.2017.154
_version_ 1783460335960719360
author Joelle Greenberg, Alexandra
Staff, Nathan P.
Windebank, Anthony
author_facet Joelle Greenberg, Alexandra
Staff, Nathan P.
Windebank, Anthony
author_sort Joelle Greenberg, Alexandra
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: Translating conventional and regenerative medicine strategies from the research laboratory into the clinic is a complex process that can delay bringing novel therapies to the patient. Navigating the increasingly complex regulation surrounding cell-based and combination product technologies is a major challenge for the translational biomedical scientist. To this end, Mayo Clinic created a new position, the “Translational Integrator,” as part of the cGMP Biomaterials Facility in the Center for Regenerative Medicine. METHODS/STUDY POPULATION: The Translational Integrator educates investigators about FDA standards and regulatory pathways; determines where the product is on the translational spectrum; works to understand the science behind the product; determines what additional studies may be needed; supports investigators in preparing for FDA communications and submissions; and educates researchers about institutional resources and funding mechanisms needed to move their product into manufacturing and trials. A primary objective is to meet investigators at an early stage in product development to avoid conducting potentially redundant work to meet regulatory requirements. RESULTS/ANTICIPATED RESULTS: Robust training in clinical and translational research methodology enables the integrator to facilitate the collaboration necessary between investigators, clinicians, institutional resources, regulators and funders to move products towards FDA IND/IDE approval and first-in-human trials. It is an iterative process using technology/translational readiness criteria, project management and review by subject matter experts that is highly interactive and customized to each project. Current projects include topics in orthopedic surgery and ENT. In creating and refining this position, several key lessons have been learned. DISCUSSION/SIGNIFICANCE OF IMPACT: First, the Translational Integrator must undergo constant reflection and assessment of investigator needs, which requires flexibility and understanding that their role may change in the context of each product. Second, the support that the Translational Integrator provides can shift the mindset of the investigator from being averse to engaging in the translational process to eager to move their product forward. Finally, for the investigator who does not personally want to move their work into first-in-human trials, establishing connections to intellectual property generation and licensing may support movement of their findings into patients.
format Online
Article
Text
id pubmed-6799662
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-67996622019-10-28 2018: The translational integrator: Facilitating collaboration and bridging the “Valley of Death” Joelle Greenberg, Alexandra Staff, Nathan P. Windebank, Anthony J Clin Transl Sci Education/Mentoring/Professional Development OBJECTIVES/SPECIFIC AIMS: Translating conventional and regenerative medicine strategies from the research laboratory into the clinic is a complex process that can delay bringing novel therapies to the patient. Navigating the increasingly complex regulation surrounding cell-based and combination product technologies is a major challenge for the translational biomedical scientist. To this end, Mayo Clinic created a new position, the “Translational Integrator,” as part of the cGMP Biomaterials Facility in the Center for Regenerative Medicine. METHODS/STUDY POPULATION: The Translational Integrator educates investigators about FDA standards and regulatory pathways; determines where the product is on the translational spectrum; works to understand the science behind the product; determines what additional studies may be needed; supports investigators in preparing for FDA communications and submissions; and educates researchers about institutional resources and funding mechanisms needed to move their product into manufacturing and trials. A primary objective is to meet investigators at an early stage in product development to avoid conducting potentially redundant work to meet regulatory requirements. RESULTS/ANTICIPATED RESULTS: Robust training in clinical and translational research methodology enables the integrator to facilitate the collaboration necessary between investigators, clinicians, institutional resources, regulators and funders to move products towards FDA IND/IDE approval and first-in-human trials. It is an iterative process using technology/translational readiness criteria, project management and review by subject matter experts that is highly interactive and customized to each project. Current projects include topics in orthopedic surgery and ENT. In creating and refining this position, several key lessons have been learned. DISCUSSION/SIGNIFICANCE OF IMPACT: First, the Translational Integrator must undergo constant reflection and assessment of investigator needs, which requires flexibility and understanding that their role may change in the context of each product. Second, the support that the Translational Integrator provides can shift the mindset of the investigator from being averse to engaging in the translational process to eager to move their product forward. Finally, for the investigator who does not personally want to move their work into first-in-human trials, establishing connections to intellectual property generation and licensing may support movement of their findings into patients. Cambridge University Press 2018-05-10 /pmc/articles/PMC6799662/ http://dx.doi.org/10.1017/cts.2017.154 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Education/Mentoring/Professional Development
Joelle Greenberg, Alexandra
Staff, Nathan P.
Windebank, Anthony
2018: The translational integrator: Facilitating collaboration and bridging the “Valley of Death”
title 2018: The translational integrator: Facilitating collaboration and bridging the “Valley of Death”
title_full 2018: The translational integrator: Facilitating collaboration and bridging the “Valley of Death”
title_fullStr 2018: The translational integrator: Facilitating collaboration and bridging the “Valley of Death”
title_full_unstemmed 2018: The translational integrator: Facilitating collaboration and bridging the “Valley of Death”
title_short 2018: The translational integrator: Facilitating collaboration and bridging the “Valley of Death”
title_sort 2018: the translational integrator: facilitating collaboration and bridging the “valley of death”
topic Education/Mentoring/Professional Development
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799662/
http://dx.doi.org/10.1017/cts.2017.154
work_keys_str_mv AT joellegreenbergalexandra 2018thetranslationalintegratorfacilitatingcollaborationandbridgingthevalleyofdeath
AT staffnathanp 2018thetranslationalintegratorfacilitatingcollaborationandbridgingthevalleyofdeath
AT windebankanthony 2018thetranslationalintegratorfacilitatingcollaborationandbridgingthevalleyofdeath